Antimuscarinic drug therapy for overactive bladder syndrome in the elderly – are the concerns justified?

References

• Center for Disease Control and Prevention. The state of aging and health in America 2013. Atlanta (GA): Centers for Disease Control and Prevention; US Dept of Health and Human Services; 2013 [Online]. [cited 2017 Dec 23]. Available from: http://www.cdc.gov/aging/pdf/state-aging-health-in-america-2013.pdf
   Google Scholar
• UNFPA and HelpAge. Ageing in the twenty-first century: a celebration and a challenge. 2012. [cited 2019 Jan 14]. Available from: http://www.unfpa.org/publications/ageing-twenty-first-century
   Google Scholar
• Ferrucci I, Guralnik JM, Studenski S, et al. Designing randomised, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc. 2004;52:625–634.
   PubMed Web of Science ®Google Scholar
• Looman WM, Fabbricotti IN, Blom JW, et al. The frail older person does not exist: development of frailty profiles with latent class analysis. BMC Geriatr. 2018;18:84.
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21:167–178.
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/international Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.
   PubMed Web of Science ®Google Scholar
• Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6(Suppl 11):S565–73.
   PubMed Web of Science ®Google Scholar
• DuBeau CE, Kuchel GA, Johnson IIT, et al. Incontinence in the frail elderly: report from the 4th International consultation on incontinence. Neurourol Urodyn. 2010;29:165–178.
   PubMed Web of Science ®Google Scholar
• DuBeau CE. The aging lower urinary tract. J Urol. 2006;175:811–815.
   PubMed Web of Science ®Google Scholar
• Aharony L, De Cock J, Nuotio MS, et al. Consensus document on the detection and diagnosis of urinary incontinence in older people. Eur Geriatric Med. 2017;8:202–209.
   Web of Science ®Google Scholar
• Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005;48:5–26.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;58:543–562.
   Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740–764.
   PubMed Web of Science ®Google Scholar
• Madhuvrata P, Singh M, Hasafa Z, et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systemic review and meta-analysis. Eur Urol. 2012;62:816–830.
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781.
   PubMed Web of Science ®Google Scholar
• Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62:1040–1060.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Herschorn S, Snijder R, et al. Does BMI, gender or age affect efficacy of solifenacin in the management of the overactive bladder? Int Urogynecol J. 2017;28:477–488.
   PubMed Web of Science ®Google Scholar
• Samuelsson E, Odeberg J, Stenzelius K, et al. Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: A systematic review. Geriatr Gerontol Int. 2015;15(5):521–534.
   PubMed Web of Science ®Google Scholar
• Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59:377–386.
   PubMed Web of Science ®Google Scholar
• Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10(5):751–765.
   PubMed Web of Science ®Google Scholar
• Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198–203.
   PubMed Web of Science ®Google Scholar
• Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821–827.
   PubMed Web of Science ®Google Scholar
• Wagg A. Treating overactive bladder in the elderly. Can Urol Assoc J. 2011;5(Suppl 2):S149–S151.
   PubMedGoogle Scholar
• Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol. 2003;54:235–238.
   PubMed Web of Science ®Google Scholar
• Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169:1317–1324.
   PubMed Web of Science ®Google Scholar
• Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the elderly population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–1483.
   PubMed Web of Science ®Google Scholar
• Cai X, Campbell N, Khan B, et al. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013;9:377–385.
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604–615.
   PubMed Web of Science ®Google Scholar
• Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315.
   PubMedGoogle Scholar
• Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–732.
   PubMed Web of Science ®Google Scholar
• Averbeck MA, Altaweel W, Manu-Marin A, et al. Management of LUTS in patients with dementia and associated disorders. Neurourol Urodyn. 2017;36:245–252.
   PubMed Web of Science ®Google Scholar
• Del-Ser T, Munoz DG, Haschinski V. Temporal patterns of cognitive decline and incontinence is different in Alzheimer’s disease and diffuse Lewy body disease. Neurology. 1996;46:682–686.
   PubMed Web of Science ®Google Scholar
• Ransmayr GN, Hollinger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. J Neurol. 2008;70:299–303.
   Google Scholar
• Wagg A. Managing special populations: the elderly. Eur Urol Suppl. 2006;5:866–870.
   Web of Science ®Google Scholar
• Paquette A, Gou P, Tannenbaum C. Systematic review and meta- analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59:1332–1339.
   PubMed Web of Science ®Google Scholar
• Kersten H, Wyller TB. Anticholinergic drug burden in older people’s brain – how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114(2):151–159.
   PubMed Web of Science ®Google Scholar
• Salahudeen MS, Chyou TY, Nishtala PS. Serum Anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature. PLoS One. 2016;11(3):e0151084.
   PubMed Web of Science ®Google Scholar
• Villalba-Moreno AM, Alfaro-Lara ER, Perez-Guerrero MC, et al. Systematic review on the use of anticholinergic scales in polypathological patients. Arch Gerontol Geriatr. 2016;62:1–8.
   PubMed Web of Science ®Google Scholar
• Kay GG, Maruff P, Scholfield D, et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgrad Med. 2012;124(3):7–15.
   PubMed Web of Science ®Google Scholar
• DuBeau C, Kraus SR, Griebling TL, et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: A double-blind, placebo-controlled study. J Urol. 2012;187(4S):e548–549.
   Google Scholar
• Wagg A, Arumi D, Herschorn S, et al. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing. 2017;46(4):620–626.
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomised, double-blind, placebo-controlled study of fesoterodine in an ageing population trial. J Am Geriatr Soc. 2013;61:185–193.
   PubMed Web of Science ®Google Scholar
• Wagg A, Dale M, Tretter R, et al. Randomised, multi-centre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64:74–81.
   PubMed Web of Science ®Google Scholar
• Hampel C, Betz D, Berger M, et al. Solifenacin in the elderly: results of an observational study measuring efficacy, tolerability and cognitive effects. Urol Int. 2017;98:350–357.
   PubMed Web of Science ®Google Scholar
• Burkhard FC, Bosch JLHR, Cruz F et al. EAU guidelines on urinary incontinence in adults. European Association of Urology, 2018. [cited 2018 Dec 20]. Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urinary-Incontinence-2018-large-text.pdf.
   Google Scholar
• National Institute for Health and Care Excellence. Urinary incontinence in women: management. Clinical Guideline. [ cited 29 April 2018]. Available form: www.nice.org.uk/guidance/cg171.
   Google Scholar
• Rai BP, Cody JD, Alhasso A, et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults (review). Cochrane Lib Database Syst Rev. 2012 12.
   Google Scholar
• Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel ß3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with effects of oxybutynin. Eur Urol. 2012;62(6):1165–1173.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Mirabegron: A review in overactive bladder syndrome. Drugs. 2018;78(8):833–844.
   PubMed Web of Science ®Google Scholar
• Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43:666–675.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30.
   PubMed Web of Science ®Google Scholar
• Heesakkers JPFA, Digesu GA, van Breda J, et al. A novel leadless, miniature implantable tibial nerve neuromodulation system for the management of overactive bladder complaints. Neurourol Urodyn. 2018;37(3):1060–1067.
   PubMed Web of Science ®Google Scholar
• Cohn JA, Kowalik CG, Kaufman MR, et al. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. Expert Rev Med Devices. 2017;14(1):3–14.
   PubMed Web of Science ®Google Scholar